Patent ID: 7851456
Filing Date: 2010-12-14
Classification: A61K,A61P

Abstract:
1. A method of enhancing or facilitating the clearance of the lung mucus secretions of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I, or a pharmaceutically acceptable salt thereof, in an amount sufficient to clear mucus secretions; wherein: B is a purine or a pyrimidine residue according to general Formulae IV or V; n and p=0 or 1; such that the sum of n+p is from 0 to 2, with the proviso that when A=M, the sum of n+p is 1; X T M=H Y=OR Z=OR A=M, or A is a nucleoside residue which is defined as: wherein: D=O; Z′=H or OH; Y′=H or OH; B′ is a purine or a pyrimidine residue according to general Formulae IV or V which is linked to the 1′-position of the furanose or carbocycle via the 9-or 1-position of the base, respectively; R wherein O is the corresponding 2′- and/or 3′-oxygen of the furanose; C is a carbon atom; R R R R R R wherein the O atoms are the 2′- and 3′-oxygens of a furanose; and the 2′- and 3′-oxygens of the furanose are linked by a common carbon atom (C) to form a cyclical acetal, cyclical ketal, or cyclical orthoester; for cyclical acetals and ketals, R for cyclical orthoesters, R B and B′ are independently a purine residue, as in Formula IV, linked through the 9-position, or a pyrimidine residue, as in Formula V, linked through the 1-position; wherein: R R when R R R R R wherein C is a carbon atom; W R R R